Cubist Systematic Strategies LLC Purchases New Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Cubist Systematic Strategies LLC acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 152,312 shares of the company’s stock, valued at approximately $708,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI boosted its position in shares of GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after purchasing an additional 2,151 shares in the last quarter. Gagnon Securities LLC increased its stake in GoodRx by 9.9% in the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock valued at $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank increased its stake in GoodRx by 4.1% in the 4th quarter. Swiss National Bank now owns 161,400 shares of the company’s stock valued at $751,000 after buying an additional 6,400 shares during the last quarter. RPO LLC acquired a new stake in GoodRx in the 4th quarter valued at $52,000. Finally, Versor Investments LP acquired a new position in shares of GoodRx during the 4th quarter worth about $54,000. 63.77% of the stock is owned by institutional investors.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.01 on Friday. GoodRx Holdings, Inc. has a twelve month low of $3.68 and a twelve month high of $9.26. The firm has a fifty day simple moving average of $4.46 and a 200 day simple moving average of $4.69. The company has a market capitalization of $1.54 billion, a PE ratio of -133.67, a P/E/G ratio of 2.46 and a beta of 1.24. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. GoodRx’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 earnings per share. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Analyst Ratings Changes

GDRX has been the topic of several recent analyst reports. Truist Financial lowered their price objective on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating on the stock in a research note on Thursday, April 10th. UBS Group cut their price objective on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a report on Tuesday. The Goldman Sachs Group reduced their price target on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Finally, Wells Fargo & Company reduced their price target on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.33.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.